The University of Texas Health Science Center at San Antonio dedicated its new $472 million Multispecialty and Research Hospital, the only facility of its kind in South Texas where patients will have access to top specialists and pioneering therapies, especially in cancer treatment.

After a comprehensive two-year follow-up, researchers at the UCLA Health Jonsson Comprehensive Cancer Center found that MRI-guided stereotactic body radiotherapy (SBRT) for prostate cancer significantly reduced long-term side effects and improved quality of life, particularly in bowel and sexual health, compared to conventional CT-guided treatment.

Many bacterial-linked illnesses, such as inflammatory bowel disease or colorectal cancer, are associated with an overgrowth of gut bacteria thought to be bad actors. But when researchers used a machine learning algorithm to predict the density of microbes—called microbial load, from their gut microbiomes, they found that changes in microbial load, rather than the disease, could be a driver behind the presence of disease-associated microbial species.

CAR-T cells show promise against pediatric diffuse midline gliomas, brain and spinal cord tumors that are among the deadliest cancers, a Stanford Medicine trial found.

Researchers have developed an AI powered model that — in 10 seconds — can determine during surgery if any part of a cancerous brain tumor that could be removed remains, a study published in Nature suggests. The technology, called FastGlioma, outperformed conventional methods for identifying what remains of a tumor by a wide margin. Researchers say it has the potential to change the field of neurosurgery by immediately improving comprehensive management of patients with diffuse gliomas.

Scientists have identified new gene faults and evolutionary patterns contributing to testicular cancer. Their findings offer profound insights into the development of the disease and into potential treatment strategies. 

Among the key findings are:

 

New potential cancer drivers in testicular cancer, including drivers specific to certain subtypes, which may help stratify patients based on their tumour characteristics

A reconstruction of evolutionary trajectories of genome alterations and probable progression pathways in TGCT

Discovery of a broader range of mutational signatures associated with TGCT. These are distinctive patterns of DNA damage, which can reflect various carcinogenic exposures (e.g. smoking, UV light) and enable a retrospective look at exposure-related cancer risk

Previously unidentified recurrent mutational hotspots in testicular cancer

Identification of a genomic immune mechanism unique to TGCT, predominantly in seminomas, the most common tumour subtype.